Dmitry Balyasny’s Harmony Biosciences HRMY Stock Holding History

Dmitry Balyasny’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-64,600	Closed	-$1.81M	–	3215
2026 Q1	$1.81M	Buy	+64,600	New	+$2.12M	﹤0.01%	1830

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's HRMY Position: Q4 2023 in Review

Dmitry Balyasny sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 254,650 shares — an estimated $8.34M sold.

Dmitry Balyasny first reported a position in HRMY in Q3 2021 and held it in 4 quarters. The position peaked at $15.3M in Q1 2023. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

Dmitry Balyasny reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
Dmitry Balyasny sold 254,650 Harmony Biosciences shares in Q4 2023, an estimated $8.34M.
Dmitry Balyasny first reported a position in Harmony Biosciences in Q3 2021 and held it in 4 quarters.
Dmitry Balyasny's Harmony Biosciences position peaked at $15.3M in Q1 2023.
221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.